Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer
Recruiting
N/A
Interventional Study
Non-small Cell Lung Cancer
Minimal Residual Disease
Adaptive Treatment
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 1,000 (estimated)
- Sponsor
- Peking University People's Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The goal of this study is to develop new techniques for minimal residual disease(MRD) monitoring and to confirm the efficacy and safety of MRD-guided postoperative management for early stage non-small cell lung cancer. The main questions this study aims to answer are:
* How to develop multi-omics-based high-sensitivity detection methods to accurately capture MRD and monitor postoperative recurren…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Non-small cell lung cancer with stage IA-IIIA (8th edition TNM classification) planning to undergo curative surgery or to undergo neoadjuvant therapy
* Solid nodules \>1 cm or ground-glass nodules \>1.5 cm on imaging
* No history of malignancies other than non-small cell lung …
Contacts